KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target
Lung neoplasms are the leading cause of death by cancer worldwide. Non-small cell lung
cancer (NSCLC) constitutes more than 80% of all lung malignancies and the majority of …
cancer (NSCLC) constitutes more than 80% of all lung malignancies and the majority of …
[HTML][HTML] How long is too long? A scoping review of health system delays in lung cancer
A Malalasekera, S Nahm, PL Blinman… - European …, 2018 - Eur Respiratory Soc
Earlier access to lung cancer specialist (LCS) care improves survival, highlighting the need
for streamlined patient referral. International guidelines recommend 14-day maximum time …
for streamlined patient referral. International guidelines recommend 14-day maximum time …
Meta‐analysis of microRNA expression in lung cancer
The prognostic and diagnostic value of microRNA (miRNA) expression aberrations in lung
cancer has been studied intensely in recent years. However, due to the application of …
cancer has been studied intensely in recent years. However, due to the application of …
Development and in vitro evaluation of core–shell type lipid–polymer hybrid nanoparticles for the delivery of erlotinib in non-small cell lung cancer
B Mandal, NK Mittal, P Balabathula, LA Thoma… - European journal of …, 2016 - Elsevier
Core–shell type lipid–polymer hybrid nanoparticles (CSLPHNPs) have emerged as a
multifunctional drug delivery platform. The delivery system combines mechanical …
multifunctional drug delivery platform. The delivery system combines mechanical …
The integrated stress response is tumorigenic and constitutes a therapeutic liability in KRAS-driven lung cancer
N Ghaddar, S Wang, B Woodvine… - Nature …, 2021 - nature.com
The integrated stress response (ISR) is an essential stress-support pathway increasingly
recognized as a determinant of tumorigenesis. Here we demonstrate that ISR is pivotal in …
recognized as a determinant of tumorigenesis. Here we demonstrate that ISR is pivotal in …
miR-335-5p inhibits TGF-β1-induced epithelial–mesenchymal transition in non-small cell lung cancer via ROCK1
W Du, H Tang, Z Lei, J Zhu, Y Zeng, Z Liu, J Huang - Respiratory research, 2019 - Springer
Background Significant evidence has shown that the miRNA pathway is an important
component in the downstream signaling cascades of TGF-β1 pathway. Our previous study …
component in the downstream signaling cascades of TGF-β1 pathway. Our previous study …
Developing a copper (II) agent based on his-146 and his-242 residues of Human serum albumin nanoparticles: integration to overcome cisplatin resistance and inhibit …
M Jiang, Z Zhang, W Li, X Man, H Sun… - Journal of Medicinal …, 2022 - ACS Publications
To overcome the resistance of nonsmall cell lung cancer (NSCLC) cells to cisplatin and
inhibit their metastasis, we proposed to develop a Cu (II) agent based on the specific residue …
inhibit their metastasis, we proposed to develop a Cu (II) agent based on the specific residue …
[HTML][HTML] Platinum complexes of curcumin delivered by dual-responsive polymeric nanoparticles improve chemotherapeutic efficacy based on the enhanced anti …
Y Chen, C Chen, X Zhang, C He, P Zhao, M Li… - … Pharmaceutica Sinica B, 2020 - Elsevier
Platinum-based chemotherapy is used for non-small cell lung cancer (NSCLC). However, it
has side effects and minimum efficacy against lung cancer metastasis. In this study, platinum …
has side effects and minimum efficacy against lung cancer metastasis. In this study, platinum …
LncRNA MALAT1 promotes migration and invasion of non-small-cell lung cancer by targeting miR-206 and activating Akt/mTOR signaling
Y Tang, GM Xiao, YJ Chen, Y Deng - Anti-Cancer Drugs, 2018 - journals.lww.com
Long noncoding RNA (lncRNA) metastasis-associated lung adenocarcinoma transcript 1
(MALAT1) functions as a crucial regulator of metastasis in lung cancer. The aim of this study …
(MALAT1) functions as a crucial regulator of metastasis in lung cancer. The aim of this study …
[HTML][HTML] Enhanced in vitro and in vivo anticancer activity through the development of Sunitinib-Loaded nanoniosomes with controlled release and improved uptake
S Dehghan, A Naghipour, FZ Anbaji… - International Journal of …, 2023 - Elsevier
This study aims to develop sunitinib niosomal formulations and assess their in-vitro anti-
cancer efficiency against lung cancer cell line, A549. Sunitinib, a highly effective anticancer …
cancer efficiency against lung cancer cell line, A549. Sunitinib, a highly effective anticancer …